Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients

Cholangiocarcinoma Clinical Trial

Official title:

Clinical Study on the Drug Sensitivity Consistency of Patient-Derived Organoid Model and Actual Therapeutic Efficacies in Cholangiocarcinoma Patients Receiving Adjuvant Chemotherapy After Radical Resection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05634694
• Other study ID #: SYSKY-2022-168-01
• Status: Recruiting
• Start date: November 30, 2022
• Est. completion date: December 1, 2024

Study information

• Verified date: November 2022
• Source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Contact: Honghua Zhang, PhD
• Phone: 020-34078840
• Email: zhanghh68[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the consistency and accuracy of patient-derived organoid model of cholangiocarcinoma to predict the clinical chemotherapeutic efficacy, as well as the possibility of guiding the adjuvant chemotherapy.

Description:

The chemotherapeutic efficacy is heterogeneous among cholangiocarcinoma patients after radical resection, and an accurate and relatively convenient model evaluating the chemotherapeutic efficacy is still lacking. This study aims to prospectively evaluate the consistency of drug sensitivity between patient-derived organoid model and the actual clinical chemotherapeutic efficacy in cholangiocarcinoma patients, assisting in guiding precision medicine and making therapeutic decisions.

Drug sensitivity tests include single drug and drug combination. The organoids that are successfully cultured will be kept in liquid nitrogen for a specific time.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 1, 2024
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The patient must sign an informed consent form;

2. Age 18-75 years old, both male and female;

3. ECOG performance status score (PS score) 0-2;

4. Child-Pugh score A period;

5. Cholangiocarcinoma with negative margins confirmed by histopathology;

6. Have not received any systemic treatment within 6 months;

7. The functional indicators of important organs meet the following requirements (1)Neutrophils=1.5*109/L; platelets=100*109/L; hemoglobin=9g/dl; serum albumin=3g/dl; (2)Thyroid-stimulating hormone (TSH) = 2 times the upper limit of normal, and T3 and T4 are in the normal range; (3)Bilirubin = 1.5 times the upper limit of normal; ALT and AST = 3 times the upper limit of normal; (4)Serum creatinine = 1.5 times the upper limit of normal, and creatinine clearance = 60ml/min (calculated by Cockcroft-Gault formula);

8. For women who are not breastfeeding or pregnant, use contraception during treatment or 12 months after the end of treatment.

Exclusion Criteria:

1. Unresectable cholangiocarcinoma patients or postoperative diagnosis of cholangiocarcinoma recurrence and metastasis;

2. Past or simultaneous suffering from other malignant tumors;

3. Have used gemcitabine-based chemotherapy or radiotherapy within 6 months;

4. Severe cardiopulmonary and renal dysfunction;

5. Hypertension that is difficult to control with drugs (systolic blood pressure (BP) =140 mmHg and/or diastolic blood pressure =90mmHg) (based on the average of =3 BP readings obtained by =2 measurements);

6. Abnormal coagulation function (PT>14s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy;

7. After antiviral treatment, HBV DNA>2000 copies/ml, HCV RNA>1000;

8. A history of esophageal and gastric varices, significant clinically significant bleeding symptoms or a clear tendency to appear within 3 months before enrollment;

9. Active infections requiring systemic treatment; patients with active tuberculosis infection within 1 year before enrollment; a history of active tuberculosis infection more than 1 year before enrollment, and no formal anti-tuberculosis treatment or tuberculosis Still in the active period;

10. Human immunodeficiency virus (HIV, HIV1/2 antibody) positive;

11. A history of psychotropic drug abuse, alcohol or drug abuse;

12. Known to have a history of severe allergies to any platinum drugs, or gemcitabine;

13. Other factors judged by the investigator may affect the safety of the subjects or the compliance of the trial. Such as serious diseases (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.

Related Conditions & MeSH terms

• Cholangiocarcinoma
• Hypersensitivity

Intervention

Other:
• No interventions.
No interventions.

Locations

Country	Name	City	State
China	Sun Yat-sen Memorial Hospital, Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival status of cholangiocarcinoma patients after radical resection	The cholangiocarcinoma patients after radical resection are regularly followed-up for the progression-free survival status.	12 months
Primary	Drug sensitivity of patient-derived tumor organoids	The drug sensitivity is tested on patient-derived tumor organoids, which is evaluated using Promega CellTiter-Glo 3D Cell Viability Assay to calculate the relative IC50, and is compared with the actual chemotherapeutic efficacy of cholangiocarcinoma patients.	2 months